ArticleCurrent stem cell reports2017
Bioartificial Kidneys.
Article in Current stem cell reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Artificial Intelligence in the Intensive Care Unit: Current Evidence on an Inevitable Future Tool.Cureus · 2024Review
- Capturing effects of blood flow on the transplanted decellularized nephron with intravital microscopy.Scientific reports · 2023Article
- Gray level co-occurrence matrix and wavelet analyses reveal discrete changes in proximal tubule cell nuclei after mild acute kidney injury.Scientific reports · 2023Article
- From waste to wealth: Repurposing slaughterhouse waste for xenotransplantation.Frontiers in bioengineering and biotechnology · 2023Article
- Computational approaches for evaluating morphological changes in the corneal stroma associated with decellularization.Frontiers in bioengineering and biotechnology · 2023Article
- A scalable corneal xenograft platform: simultaneous opportunities for tissue engineering and circular economic sustainability by repurposing slaughterhouse waste.Frontiers in bioengineering and biotechnology · 2023Article
- A proposed model of xeno-keratoplasty using 3D printing and decellularization.Frontiers in pharmacology · 2023Article
- Enhancing the expression of a key mitochondrial enzyme at the inception of ischemia-reperfusion injury can boost recovery and halt the progression of acute kidney injury.Frontiers in physiology · 2023Article
- Still finding ways to augment the existing management of acute and chronic kidney diseases with targeted gene and cell therapies: Opportunities and hurdles.Frontiers in medicine · 2023Review
- Acellular Tissue-Engineered Vascular Grafts from Polymers: Methods, Achievements, Characterization, and Challenges.Polymers · 2022Review
- Digital Technologies: Advancing Individualized Treatments through Gene and Cell Therapies, Pharmacogenetics, and Disease Detection and Diagnostics.Biomedicines · 2022Article
- Intravital microscopy datasets examining key nephron segments of transplanted decellularized kidneys.Scientific data · 2022Article
- Differentiated kidney tubular cell-derived extracellular vesicles enhance maturation of tubuloids.Journal of nanobiotechnology · 2022Article
- Review
- Mitigating challenges and expanding the future of vascular tissue engineering-are we there yet?Frontiers in physiology · 2022Article
- Analysis of Vascular Architecture and Parenchymal Damage Generated by Reduced Blood Perfusion in Decellularized Porcine Kidneys Using a Gray Level Co-occurrence Matrix.Frontiers in cardiovascular medicine · 2022Article
- Decellularized blood vessel development: Current state-of-the-art and future directions.Frontiers in bioengineering and biotechnology · 2022Review
- Renal Biology Driven Macro- and Microscale Design Strategies for Creating an Artificial Proximal Tubule Using Fiber-Based Technologies.ACS biomaterials science & engineering · 2021Review
- In vitro investigation of the impact of pulsatile blood flow on the vascular architecture of decellularized porcine kidneys.Scientific reports · 2021Article
- Intravital imaging of real-time endogenous actin dysregulation in proximal and distal tubules at the onset of severe ischemia-reperfusion injury.Scientific reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
purpose of reviewHistorically, there have been many advances in the ways in which we treat kidney diseases. In particular, hemodialysis has set the standard for treatment since the early 1960s and continues today as the most common form of treatment for acute, chronic, and end-stage conditions. However, the rising global prevalence of kidney diseases and our limited understanding of their etiologies have placed significant burdens on current clinical management regimens. This has resulted in a desperate need to improve the ways in which we treat the underlying and ensuing causes of kidney diseases for those who are unable to receive transplants. RECENT
findingsOne way of possibly addressing these issues is through the use of improved bioartificial kidneys. Bioartificial kidneys provide an extension to conventional artificial kidneys and dialysis systems, by incorporating aspects of living cellular and tissue function, in an attempt to better mimic normal kidneys. Recent advancements in genomic, cellular, and tissue engineering technologies are facilitating the improved design of these systems. SUMMARY: In this review, we outline various research efforts that have focused on the development of regenerated organs, implantable constructs, and whole bioengineered kidneys, as well as the transitions from conventional dialysis to these novel alternatives. As a result, we envision that these pioneering efforts can one day produce bioartificial renal technologies that can either perform or reintroduce essential function, and thus provide practical options to treat and potentially prevent kidney diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.